NCT05329246

Brief Summary

This study aimed to analyze and investigate whether the use of the PMcardio clinical assistant leads to a more efficient patient management in primary care and more accessible specialised care compared to usual standards of care and to assess the reliability and safety of the PMcardio smartphone application in the primary care use environment. Additionally, to evaluate time savings and cost saving implications of increased availability of specialised care at the primary care level.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
836

participants targeted

Target at P75+ for not_applicable cardiovascular-diseases

Timeline
Completed

Started Nov 2021

Shorter than P25 for not_applicable cardiovascular-diseases

Geographic Reach
1 country

56 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 22, 2021

Completed
21 days until next milestone

First Submitted

Initial submission to the registry

December 13, 2021

Completed
4 months until next milestone

First Posted

Study publicly available on registry

April 14, 2022

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2022

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2022

Completed
Last Updated

August 2, 2022

Status Verified

July 1, 2022

Enrollment Period

7 months

First QC Date

December 13, 2021

Last Update Submit

July 29, 2022

Conditions

Keywords

Cardiovascular DiseasesMedical DevicePrimary Health CareDiagnostic ToolArtificial InteligenceA.I. Clinical AssistantPowerful MedicalPMcardioElectrocardiogramECGECG Diagnostic

Outcome Measures

Primary Outcomes (4)

  • Time to first cardiovascular-related consultation

    Time from randomization to the first cardiovascular-related consultation or a follow-up visit at specialized physician in patients, where specialized consultation is indicated based on the general practitioner recommendation after using PMcardio application. The measurement will be assessed from the data received from the health insurance provider.

    From randomization to enrollment period completion (up to 6 months)

  • Time to first cardiovascular-related diagnostic testing

    Time from randomization to the first cardiovascular-related further diagnostic testing (laboratory parameters, ECG Holter, echocardiography).The measurement will be assessed from the data received from the health insurance provider

    From randomization to to enrollment period completion (up to 6 months)

  • Time to first cardiovascular-related hospitalization

    Time from randomization to the first hospitalization in patients, where hospitalization is indicated, based on the general practitioner recommendation while using PMcardio application. The measurement will be assessed from the data received from the health insurance provider

    From randomization to to enrollment period completion (up to 6 months)

  • Time to first cardiovascular-related drug prescription

    Time from randomization to the first cardiovascular-related drug prescription in patients, where drug prescription is indicated, based on the general practitioner recommendation while using PMcardio application. The measurement will be assessed from the data received from the health insurance provider

    From randomization to to enrollment period completion (up to 6 months)

Secondary Outcomes (4)

  • Cost-effectiveness ratio and effect on cost savings

    1 year

  • Reliability and safety of the PMcardio measured by system up-time

    From the very first participants randomization to total follow-up time (up to 6 months)

  • Reliability and safety of the PMcardio measured by system failures

    From the very first participants randomization to total follow-up time (up to 6 months)

  • General practitioner satisfaction assessed by Client Satisfaction Questionnaire (CSQ-8 scale).

    From randomization to study completion (up to 1 year)

Study Arms (2)

Experimental Intervention Group

EXPERIMENTAL

AI-assisted interpretation of the ECG including the predicted ECG diagnoses, disease-specific anamnestic questions, and patient management recommendations for referral to secondary care, including suggestions for procedures and further diagnostic tests

Device: AI-assisted Clinical Assistant PMcardio

Control Group

NO INTERVENTION

The usual standard of care, with NO AI-based diagnosis or treatment recommendation available.

Interventions

PMcardio is an AI-powered clinical assistant in the form of a mobile application empowering non-cardiologist healthcare workers with advanced cardiovascular diagnostic capabilities, recommending patient-specific suggestions for referral and facilitating remote consultations with specialized cardiologists.

Experimental Intervention Group

Eligibility Criteria

Age55 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Male or Female aged 55 years or above.
  • Participant is willing and able to give informed consent for participation in the study.
  • Presenting to the GP with ANY of the following cardiovascular symptoms: palpitations, chest pain, syncope, shortness of breath.
  • Patients insured by Dôvera ZP or Union ZP health insurance providers.

You may not qualify if:

  • Reason for doing the ECG at the GP clinic is a routine examination or pre-operative assessment.
  • Participant does not present with cardiovascular symptoms: palpitations, chest pain, syncope, shortness of breath.
  • Participant is already included in the study due to a prior GP visit throughout the trial period (e.g., participant comes for a second visit to GP clinic due to cardiovascular symptoms).
  • Patients insured by VšZP health insurance provider
  • Female participants who are pregnant, lactating or planning pregnancy during the study.
  • Any other significant comorbidity, disease, or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the study, or may influence the result of the study, or the participant's ability to participate in the study.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (56)

MUZMED s.r.o.

Bardejov, Slovakia

Location

MAR-BID s.r.o.

Bidovce, Slovakia

Location

SIMAMED, s.r.o.

Borský Mikuláš, Slovakia

Location

SollarMED, s.r.o.

Bratislava, Slovakia

Location

NÁGEL, s.r.o.

Búč, Slovakia

Location

MEDIFARMA s.r.o.

Dolný Kubín, Slovakia

Location

Promedicum, s.r.o.

Hanušovce nad Topľou, Slovakia

Location

GP Humenné, s.r.o.

Humenné, Slovakia

Location

LPSo spol. s r.o.

Humenné, Slovakia

Location

MED - AID s.r.o.

Humenné, Slovakia

Location

MUDr. Peter Križalkovič

Hurbanovo, Slovakia

Location

MUDr. Ildikó Papáčková

Kolárovo, Slovakia

Location

BELLIS-med s.r.o.

Komárno, Slovakia

Location

MEDIKONTAKT, s.r.o.

Komárno, Slovakia

Location

IRS - Medicínska činnosť s.r.o.

Košice, Slovakia

Location

MUCOMED s.r.o.

Košice, Slovakia

Location

MUDr. Ján Telepovský

Košice, Slovakia

Location

SANABITUR, s.r.o.

Križovany Nad Dudváhom, Slovakia

Location

Anahata s.r.o.

Lenartovce, Slovakia

Location

FONTHIS, s.r.o.

Levice, Slovakia

Location

MUDr. Mária Schmidtová, s.r.o.

Martin, Slovakia

Location

Vaša ambulancia, s. r. o.

Martin, Slovakia

Location

MUDr. Ondrej Gajdoš

Medzev, Slovakia

Location

Medic I+H s.r.o.

Medzilaborce, Slovakia

Location

JANMED, s.r.o.

Michalovce, Slovakia

Location

Cardio Clinic s.r.o.

Moldava nad Bodvou, Slovakia

Location

G.Praktik s.r.o.

Moldava nad Bodvou, Slovakia

Location

HODOSI-MED s.r.o

Moldava nad Bodvou, Slovakia

Location

Tamice,s.r.o.

Moldava nad Bodvou, Slovakia

Location

LEK - NO, s.r.o.

Námestovo, Slovakia

Location

TOMICI s.r.o.

Nesvady, Slovakia

Location

Timimed s. r. o.

Nitra, Slovakia

Location

VERKIAD s.r.o.

Nitra, Slovakia

Location

VALETUDO s.r.o.

Nitrianske Hrnčiarovce, Slovakia

Location

RODMED s.r.o.

Nové Zámky, Slovakia

Location

Duo medical s.r.o.

Pezinok, Slovakia

Location

PALMED, s.r.o.

Podolínec, Slovakia

Location

MEDIPRAX s.r.o

Poprad, Slovakia

Location

PULSE medicine, s.r.o

Poprad, Slovakia

Location

GP - PRAKTIK, s.r.o.

Prešov, Slovakia

Location

KNG s.r.o.

Prešov, Slovakia

Location

MDPRAK, s.r.o.

Prešov, Slovakia

Location

RM - MEDICAL s.r.o.

Prievidza, Slovakia

Location

CorMedicus s.r.o.

Ruskov, Slovakia

Location

Jklinik s.r.o

Ružomberok, Slovakia

Location

PT Care s.r.o.

Spišský Hrušov, Slovakia

Location

MUDr. Boris Piteľ

Stakčín, Slovakia

Location

MEDICATEK s.r.o.

Starý Tekov, Slovakia

Location

VINOVA Group s.r.o.

Strekov, Slovakia

Location

AVK MEDIC, s.r.o.

Štúrovo, Slovakia

Location

GPII Medical s.r.o.

Tekovské Lužany, Slovakia

Location

MUDr. Peter MARKO, s.r.o.

Veľká Lomnica, Slovakia

Location

Resutík s.r.o.

Veľký Krtíš, Slovakia

Location

MUDr. Viera Čuchranová

Vinne, Slovakia

Location

JOMED, spol. s r.o.

Vranov nad Topľou, Slovakia

Location

MUDr. Orság Juraj, s.r.o.

Želiezovce, Slovakia

Location

Related Links

MeSH Terms

Conditions

Cardiovascular DiseasesDyspneaChest PainSyncope

Condition Hierarchy (Ancestors)

Respiration DisordersRespiratory Tract DiseasesSigns and Symptoms, RespiratorySigns and SymptomsPathological Conditions, Signs and SymptomsPainNeurologic ManifestationsUnconsciousnessConsciousness DisordersNeurobehavioral ManifestationsNervous System Diseases

Study Officials

  • Robert Hatala, PhD

    Chief Scientist and Founder

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 13, 2021

First Posted

April 14, 2022

Study Start

November 22, 2021

Primary Completion

June 30, 2022

Study Completion

June 30, 2022

Last Updated

August 2, 2022

Record last verified: 2022-07

Data Sharing

IPD Sharing
Will not share

Locations